#Scinai Immunotherapeutics #Israel #Jerusalem #Pincell #PC111

Scinai Immunotherapeutics and Pincell Hosting Webinar on Innovative Drug Candidate

On May 7, 2025, Scinai Immunotherapeutics Ltd. will hold an informative webinar addressing the urgent needs for effective treatments in rare dermatological diseases. This event will spotlight PC111, an innovative drug candidate that holds promise in changing the treatment landscape for conditions like Pemphigus Vulgaris and Stevens-Johnson Syndrome (SJS)/Toxic Epidermal Necrolysis (TEN).

About the Webinar

Scheduled for 11:30 AM EST (6:30 PM Israel time), the webinar will be streamed live on LinkedIn and YouTube, offering experts and interested participants to engage in a crucial dialogue. Attendees will delve into the issues surrounding the treatment of these severe conditions while examining how PC111 can offer solutions.

The discussion will also cover Pincell’s innovative monoclonal antibody drug that specifically targets the soluble Fas ligand, providing insights into its potential effectiveness in managing these previously hard-to-treat diseases.

Expert Panel Line-Up

The session will be led by a team of accomplished professionals:

• - Amir Reichman, CEO of Scinai Immunotherapeutics
• - Prof. Carlo Pincelli, Co-founder and CMO of Pincell
• - Dr. Antonino Amato, Chairman and CEO of Pincell
• - Dr. Jonathan Sadeh, CMO of Bausch Health and Scinai Advisory Board member
• - Prof. Michael Schön, Head of Dermatology at UMG and also a board member at Scinai

Registration Details

Those looking to register for the webinar can do so via a provided link that will facilitate an opportunity to submit questions for the panel discussion. This interactive Q&A segment encourages participants to delve deeper into the clinical implications and development strategies for PC111.

Understanding Pemphigus and SJS/TEN

Pemphigus Vulgaris, SJS, and TEN are debilitating autoimmune diseases that manifest through painful lesions and blisters affecting both skin and mucous membranes. Pemphigus is known for its challenging treatment protocol, often involving long-term immunosuppressive therapies that carry significant health risks, including a mortality rate of 5-10%. Similarly, SJS and the more severe TEN lead to extensive skin damage and elevated mortality rates of 5-40%, emphasizing a critical need for new treatment modalities.

PC111, being a fully human monoclonal antibody, is unique as it targets the Fas ligand to mitigate the undesired apoptosis of skin cells. Unlike some existing treatments that suppress the immune response, leading to severe side effects, PC111 aims to adopt a selective targeting approach, reducing adverse outcomes while focusing on efficacy.

A Promising Future

Pincell’s research presents substantial evidence through various experiments, including studies conducted in humanized mouse models, that underline the drug's ability to inhibit blister formation without steroid involvement. The rigorous trials indicate that PC111 could serve as a viable therapeutic alternative for managing Pemphigus and show promise against the underlying progression mechanism of SJS/TEN as demonstrated through various developmental studies.

The Future of Treatment

Given the significant market sizes and critical healthcare needs surrounding these conditions, the webinar will also elaborate on upcoming funding applications to support the continuing development of PC111, including efforts under EU’s FENG program. The decision on this grant application is anticipated in the third quarter of 2025.

Join the Conversation

As Scinai takes a step forward in revolutionizing treatment for these severe skin diseases, the webinar will serve as a platform to ignite collaboration, inform stakeholders, and foster understanding of this breakthrough approach. Stakeholders in healthcare, research, and affected communities are encouraged to attend and participate in this promising discussion.

For further information and updates, keep an eye on Scinai's website and social media channels.

Let’s drive innovation together in the quest for effective treatments for rare dermatoses!